Form 4: Major Shareholder Sells VOR Biopharma Stock

Reprogrammed Interchange LLC, a 10% owner and director, sold over 1.4 million shares of Vor Biopharma Inc. common stock.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), reported the sale of common stock.
• On August 27, 2025, 611,647 shares were sold at a weighted average price of $2.0053 per share.
• On August 28, 2025, an additional 806,351 shares were sold at a weighted average price of $2.0115 per share.
• Following these transactions, Reprogrammed Interchange LLC beneficially owns 36,884,567 shares of Vor Biopharma Inc. common stock.
• Reid Hoffman, also a director and 10% owner, is deemed a beneficial owner of securities held by Reprogrammed Interchange LLC by virtue of his shared control and indirect pecuniary interest, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The significant sale of shares by a major insider and director is generally perceived as a negative signal, potentially indicating a lack of confidence in the company's short-term prospects.

Negatives

• Significant insider selling by a 10% owner and director, Reprogrammed Interchange LLC, totaling 1,417,998 shares.
• The sales occurred at weighted average prices of $2.0053 and $2.0115, which could be interpreted as a lack of confidence at these price levels.

Risks

• Potential negative market perception due to significant insider selling, which could lead to downward pressure on the stock price.
• Reduced alignment of interests between a major shareholder/director and other shareholders following the reduction in ownership.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions are sales of common stock by Reprogrammed Interchange LLC, a 10% owner and director, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a bearish signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The substantial sale of shares by a significant insider and director, Reprogrammed Interchange LLC, suggests a potential lack of confidence in Vor Biopharma's near-term prospects. This action by a well-informed party warrants a cautious approach and could signal further downward pressure on the stock, leading to a 'sell' recommendation for investors.

Keywords

Vor Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, insider selling, Form 4, beneficial ownership, stock transaction, director sale, 10% owner